Compounded NAD+ preparations are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed. A prescription requirement does not change that distinction.
That answer can get blurred by nearby references to registered facilities, licensed pharmacies, testing laboratories, or naturally occurring ingredients. Those descriptions may have meaning, but none is a substitute for approval of the finished medicine.
Licensing and registration do not mean the compounded NAD+ medicine has FDA approval.
What compounding means in this conversation
Compounding involves preparing a medication to meet a patient’s needs under applicable requirements. The prescriber and pharmacy have responsibilities in that process. A review site cannot determine whether a particular prescription or preparation meets every relevant requirement.
Ask why the clinician is considering a compounded option and what evidence supports it for your goal. The fact that an ingredient occurs in the body does not establish the safety or usefulness of every product made with it.
A facility designation describes the facility
A state pharmacy license and FDA facility registration are not interchangeable with drug approval. The terms 503A and 503B refer to different compounding frameworks with different conditions. They do not turn an NAD+ vial into an FDA-approved product.
The Olympia review illustrates why a company’s different operations need to be distinguished. Confirm which entity and preparation apply to your order rather than relying on a general company description.
Testing addresses specific quality questions
A potency test and sterility-related testing are relevant to product quality. Even useful testing does not establish that the medication improves energy, memory, or longevity. Those are clinical effectiveness questions that require appropriate human studies.
Read the evidence guide alongside quality information. A well-described manufacturing process and a proven clinical benefit are separate claims; one does not automatically demonstrate the other.
The NAD+ safety notice adds another question
FDA’s notice about NAD+ injectable products describes reported adverse events and concerns about ingredients unsuitable for sterile compounding. Ask the pharmacy how it verifies ingredient suitability and controls contamination risks.
Avoid drawing the opposite unsupported conclusion that every compounded NAD+ product is contaminated. The point is to obtain meaningful information about the actual preparation, while recognizing that a sales page cannot eliminate uncertainty.
What to ask the clinician
Discuss the reason for treatment, alternatives, expected benefit, relevant uncertainty, and a follow-up plan. If persistent fatigue or other symptoms are driving the decision, ask whether further assessment should come first.
Our consultation checklist organizes that conversation. Our provider reviews describe services and offers; they are not certifications of regulatory compliance or medical suitability.
Ask the clinician to explain any unfamiliar regulatory language in the context of your own prescription. A clear answer should identify the actual preparation and dispensing facility, rather than rely only on a general statement about the company.
Follow the source
References & further reading
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- FDA — ingredients suitable for sterile compounding
Reports NAD+ injectable adverse events and ingredient-quality concerns.
- Grant et al. (2019) — human NAD+ infusion pilot
Small IV metabolism study; does not establish benefits of home injections.